Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· November 30, 2025

The Many Reasons to Roth

View original at nasdaq.com
The Many Reasons to Roth In this podcast, Motley Fool retirement experts Robert Brokamp and Dan Caplinger discuss five reasons why you might want to go with the Roth…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The ratio of household wealth to income is at an all time high

    80% confidence
  • The years before required minimum distributions kick in, but after you have decided to retire, sometimes that's the best time to consider a Roth conversion

    80% confidence
  • A reasonable default option for retirement plan is living to age 95, since there's a 20-25% chance that one member of a 65-year-old couple will live to their mid 90s

    80% confidence
  • When you have money in a traditional account, you basically have a co-owner of the account, the co-owner being Uncle Sam

    80% confidence
  • For a lot of folks, including a lot of Motley Fool members, those later tax rates can be higher than what you're paying now, especially if you're early in your career not paying much in taxes yet

    80% confidence
  • Household net worth is now more than eight times after tax income compared with an average of 5.5 times after tax income in the decades between World War II and the great financial crisis of 2008

    80% confidence
  • The top 10% own 87% of all equities and mutual funds

    80% confidence
  • Little by little, sometimes is the best way to get these things done with Roth conversions

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com